NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

NeuroSense published its financial results for the quarter ended June 30, 2023 and provided a business update.

Business Updates include –

  • Capital Raise of $4.5 Million
  • Phase 2b Amyotrophic Lateral Sclerosis (ALS) PARADIGM Trial Completed Patient Enrollment
  • Strategic Scientific Agreement with Biogen
  • Phase 2 Alzheimer’s Disease (AD) Trial Under Preparation

and more..


Join Our Newsletter

Skip to content